Introduction
Results of treatment for gastric cancer are reported in a nationwide registry system in Japan [1] . However, in recent years, there have been few reports of the up-todate results from each institution or hospital [2] . Panel discussion sessions at the 71st Japanese Gastric Cancer Congress (held in Tokyo, June 1999) focused on the latest results for the surgical treatment of gastric cancer at 18 representative Japanese institutions and hospitals. The results of gastric cancer treatment in Japan have improved markedly, as a result of early detection and extensive radical surgery. The proportion of patients with early gastric cancer has increased steadily, from approximately 20% in the 1970s to 50% in the 1990s [1] . Endoscopic mucosal resection (EMR) and limited surgery are commonly employed for patients with early gastric cancer [3] , while, D2 or more extensive lymph node dissection has commonly been employed safely the treatment results at each institution, the 5-year survival rates, determined by the Kaplan-Meier method, were employed.
Results

Total number of gastric cancer patients treated surgically
Gastric cancer has been a leading cause of death in Japan, but since 1993, lung cancer in males has become the number one cause of mortality. The incidence of gastric cancer has been declining dramatically in Western countries [8] . The total number of gastric cancer patients treated surgically in each institution and hospital in the period 1985 to 1994 are listed in Table 2 . None of the hospitals or institutions showed a decline in the number of gastric cancer patients treated surgically in this period. Dr. Furukawa, of the Osaka Medical Center for Cancer and Cardiovascular Disease, introduced a report from the Osaka cancer population-based registry showing a declining trend in reported gastric cancer mortality, but indicating that the morbidity of gastric cancer is still the highest among other cancers [9] . Nevertheless, in recent years, since the development of EMR, surgical resections for early gastric cancer are declining [3] . It should be noted that EMR patients will be included in the results for treatment of gastric cancer in future statistics.
Resectability
The overall resection and curative resection rates at each hospital and institution are listed in Table 2 . The rate of resection reached approximately 95% at each hospital, ranging from 89.6% to 99.3%. This highresection rate is based mainly on advances in the diagnosis of early-stage disease. Curative resection rates ranged from 62.8% to 93.7%, varying according to patient characteristics, such as the frequency of early-stage cancer, or the surgeon's attitude to advanced disease. Dr. Eguchi, of Nihon University, reported that, in their department of surgery, they treated patients with faradvanced gastric cancer with neoadjuvant chemotherapy to improve the curative resection rate.
Incidence of early gastric cancer
Double-contrast radiography and the development of fiberscopes have played a leading role in the detection of increasing numbers of early gastric cancers in Japan. The incidence of early gastric cancer at the 18 hospitals and institutions ranged from 37.9% to 59.6% (Table 3 ). In the Japanese nationwide registry, the reported frequency of early gastric cancer was 11.8% in 1965, 26.2% in 1975, and 48.4% in 1990 [1] . Dr. Yabusaki and Dr. Nashimoto, of the Niigata Cancer Center Hospital, reported the details of their increasing incidence of early gastric cancer. Five of the 18 hospitals and institutions reported rates of early gastric cancer exceeding 50%. The rate of 50% seems to be a maximum plateau of early gastric cancer detected by conventional diagnostic modalities, but with further investigations using biological techniques, a higher rate of detection of early gastric cancer may be expected.
Surgical complications
The incidence of surgical complications showed a wide range; 5.1% to 30.3% (Table 4 ). Surgical complications included leakage, bleeding, and stenosis, in addition to general complications such as pulmonary, cardiac, and renal complications. Dr. Honda, of Tokyo Medical and Dental University, reported the details of their surgical and general complications in the past 10 years. He reported that there was no evidence of increasing complications in conjunction with the increase in extensive lymphadenectomy. Dr. Arai, of Tokyo Metropolitan Komagome Hospital, reported on their continuous efforts to prevent pancreatic fistula formation after extensive lymphadenectomy.
Direct mortality
Direct mortality (i.e., operative death), defined as death within 30 postoperative days, occurred in 0.4% to 2.9% of the surgically treated patients ( Table 4) . Reduction of direct mortality to less than 0.5% was proposed as the goal for the next decade.
Five-year survival results
Five-year survival rates are listed according to depth of tumor invasion (Table 5) , lymph node metastasis (Table  6 ), stage classification (Table 7) , and curability of gastric resection (Table 8 ). Follow-up was completed in 97% to 100% of the patients in all hospitals and institutions. (Tables 5, 6) Five-year survival rates according to depth of tumor invasion ranged from 84.6% to 97.0% in T1 patients, from 46.4% to 78.9% in T2, from 17.0% to 47.2% in T3, and from 0.0% to 25.7% in T4. Five-year survival rates according to lymph node metastasis ranged from 76.8% to 93.3% in n0 patients, from 42.4% to 68.9% in n1, from 11.8% to 47.0% in n2, from 0.0% to 35.0% in n3, and from 0.0% to 11.8% in n4. Dr. Ikeguchi, of Tottori University, reported the details of survival rates by depth of tumor invasion, and Dr. Hagiwara, of Kyoto Prefectural University, reported survival rates according to lymph node metastasis. These survival rates by depth of tumor invasion and lymph node metastasis seemed to justify the propriety of the Japanese stage classification. However, we note that there were institutional differences in survival rates of T2 or more and n3-4 patients, whereas there were few institutional differences in survival rates of T1 and n0-2 patients.
Depth of tumor invasion and lymph node metastasis
Stage classification (Table 7) Good correlation was found between stage classification and the 5-year survival rates in almost all the hospitals and institutions. Dr. Curability A, No residual tumor, with high probability of cure; curability B, no residual tumor, but not evaluable as "curability A"; curability C, definite residual tumor Niigata Cancer Center, at the poster exhibition, reported changes in survival rates according to stage classification in the early and late periods. (Table 8) Five-year survival rates according to the curability of gastric resection (see Table 8 for definitions of curability A,B,C) ranged from 76.5% to 97.0% in patients with curability A, from 30.0% to 57.6% in those with curability B, and from 0.0% to 13.9% in those with curability C. Good correlation was found between curability of gastric resection and the 5-year survival rates in all hospitals and institutions. Dr. Furukawa, of Osaka Medical Center for Cancer and Cardiovascular Disease, showed the results for 5-year survival by curability of gastric resection, and reported significant differences between the three curabilities. Survival results by lymph node dissection were discussed in relation to the extent of lymph node metastasis. Dr. Omote, of the Cancer Research Institute of Kanazawa University, reported significant differences in survival results according to lymph node dissection. Dr. Arai, of Tokyo Metropolitan Hospital, reported advances in D4 lymph node dissection. The abstracts of this session clearly show that the results for D2-4 dissection (extended dissection) for n0-1 lymph node metastasis are better than those for D0-1 dissection (limited dissection). D2 lymph node dissection for n0-1 seems to be the standard gastrectomy treatment in Japan [10] .
Curability of gastric resection
Chemotherapy
Positive results for a multi-center randomized controlled trial of adjuvant chemotherapy and adjuvant immuno-chemotherapy in the Tokai area were reviewed by Dr. Yamamura, of the Aichi Cancer Center. Dr. Eguchi, of Nihon University, reported that the histopathological effects of preoperative oral 5-fluorouracil in gastric cancer may predict the chemosensitivity for each patient [11] . Dr. Otani and Dr. Kubota, of Keio University, reported the results of a multi-center clinical trial of adjuvant chemotherapy using a chemosensitivity test. Patients were divided into two groups according to the results of the histoculture drug response assay (HDRA). There was a significant difference in survival between chemo-sensitive and -resistant groups [12] . Dr. 
Less invasive surgery
The results for less invasive, limited surgery, such as wedge resection, segmental resection, pyloruspreserving gastrectomy, and laparoscopic gastrectomy, were reported. Dr. Oguma, of Tokyo Women's Medical College, reported the findings at their institution and the results for segmental resection. Dr. Kurita, of the National Shikoku Cancer Center Hospital, reviewed recurrences after limited surgery.
Discussion
The results of treatment for gastric cancer in Japan have improved markedly as a result of early detection and extensive radical surgery. The nationwide registry of gastric cancer patients was begun in 1963, and 251 996 cases were collected in the period from 1963 to 1991 [1] . Accrual data from this registry have been reported every year (Table 9 ). However, there has been no documentation of up-to-date survival data in each hospital and institution in recent years. The present report should meet the clinical need for the latest "state of the art" treatment of gastric cancer. The finding that early gastric cancer accounts for almost 50% of resected patients seems to be a triumph of the mass survey system. New treatment modalities were proposed by many hospitals for improving the treatment of advanced disease, although little progress has been achieved in this field. Standards for gastric cancer treatment have to be established, as there were considerable differences in the principles of and indications for treatment for locally advanced cancer among the representative 18 hospitals and institutions. A committee for developing practice guidelines for gastric cancer treatment was organized by the Japanese Gastric Cancer Society in 1998, and is engaged in preparing practice guidelines. These guidelines are expected to provide a baseline standard for the daily practice of gastric cancer treatment. We hope the most recent up-to-date results of gastric cancer treatment will be reported in the next 5 years. We believe that presentations of such treatment results in each hospital and institution will be useful for self-assessment and for obtaining informed consent from patients. We believe that the panel discussion sessions at the 71st Japanese Gastric Cancer Congress summarized here could contribute to future developments in gastric cancer treatment.
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